Checking New Markers for Polycystic Ovarian Syndrome in Young Women
Checks new biomarkers for polycystic ovarian syndrome in females aged 15 to 25.
Plain-language title generated from the registry record
Registry title: Polycystic Ovarian Syndrome (PCOS) Biomarker Evaluation Study
Key facts
- Where
- Erlangen, GermanySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for girls and young women aged 15 to 25 years to test new markers that may help identify PCOS (polycystic ovarian syndrome).
- Age
- 15 to 25 years
- Sex
- Female only
- Earlier treatment
- Cannot be using hormonal contraceptives.
Main reasons for not taking part
- Less than 1 year since the first period (menarche)
- Use of hormonal contraceptives
- Documented ongoing pregnancy
- Major ovarian abnormalities, such as only one ovary, or cysts and solid masses larger than 2 cm (0.8 in) on transvaginal ultrasound
- Documented cancer, or current radiation therapy or chemotherapy
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 15 and 25 years old?
Source: NCT06642831, who can take part
Where in Germany
- Department of Obstetrics and Gynecology, University Erlangen Hospital, Friedrich Alexander University of Erlangen-Nuremberg, Erlangen, GermanyErlangen, GermanyContact: Laura Lotz, DrTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University Hospital Erlangen
- Trial code
- NCT06642831
- Record updated
- 15 October 2024
- Original description
The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.Read full original descriptionShow less
Polycystic Ovarian Syndrome (PCOS) in Human Adolescent and Young Adult Females - Biomarker Evaluation Study (PHOEBE)
The purpose of the study is to validate recently identified biomarkers for the identification of PCOS in adolecent and young adult women.
Inclusion: Female subjects age 15-25 years; Signed written informed consent.
Exclusion: Malignancy ( documented malignancy, documentation of current radiation therapy or chemotherapy in medical record); Less than 1 years from onset of menarche; Use of hormonal contraceptives; Documented ongoing pregnancy; Major ovarian abnormalities, including subject with only one ovary, cysts and solid masses > 2 cm as detected by transvaginal ultrasound.